JPWO2023008427A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023008427A5 JPWO2023008427A5 JP2023538551A JP2023538551A JPWO2023008427A5 JP WO2023008427 A5 JPWO2023008427 A5 JP WO2023008427A5 JP 2023538551 A JP2023538551 A JP 2023538551A JP 2023538551 A JP2023538551 A JP 2023538551A JP WO2023008427 A5 JPWO2023008427 A5 JP WO2023008427A5
- Authority
- JP
- Japan
- Prior art keywords
- gdf15
- subject
- level
- risk
- cutoff value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021121873 | 2021-07-26 | ||
| JP2022084132 | 2022-05-23 | ||
| PCT/JP2022/028776 WO2023008427A1 (ja) | 2021-07-26 | 2022-07-26 | 慢性肝疾患における肝発癌の診断マーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023008427A1 JPWO2023008427A1 (https=) | 2023-02-02 |
| JPWO2023008427A5 true JPWO2023008427A5 (https=) | 2025-05-30 |
Family
ID=85087709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538551A Pending JPWO2023008427A1 (https=) | 2021-07-26 | 2022-07-26 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240344134A1 (https=) |
| EP (1) | EP4382912A4 (https=) |
| JP (1) | JPWO2023008427A1 (https=) |
| KR (1) | KR20240046521A (https=) |
| WO (1) | WO2023008427A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115948563A (zh) * | 2023-03-13 | 2023-04-11 | 中国医学科学院北京协和医院 | 蛋白标志物的检测试剂在制备诊断肝癌的产品中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007192557A (ja) * | 2006-01-17 | 2007-08-02 | Perseus Proteomics Inc | Ｃ型肝炎患者の肝疾患の重篤化をモニターする方法および肝癌の診断方法 |
| JP2010243406A (ja) * | 2009-04-08 | 2010-10-28 | F Hoffmann La Roche Ag | Ａｆｐおよびｐｉｖｋａ−ｉｉの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法 |
| CN101852804B (zh) * | 2010-03-29 | 2013-06-12 | 中国医学科学院病原生物学研究所 | Gdf15蛋白的抗体的新用途 |
| JP5648905B2 (ja) * | 2010-11-12 | 2015-01-07 | 株式会社Ｌｓｉメディエンス | 肝臓がん発症の検出又はリスクの予測方法 |
| WO2012108527A1 (ja) * | 2011-02-10 | 2012-08-16 | 独立行政法人理化学研究所 | 肝細胞癌への進展予測マーカー |
| JP6887278B2 (ja) | 2016-06-20 | 2021-06-16 | 株式会社東芝 | 加熱装置、画像形成装置 |
| CN107462720B (zh) * | 2017-06-19 | 2019-07-19 | 上海长海医院 | 一种opn、gdf15、nse、trap5和opg联合诊断试剂盒 |
| KR102010652B1 (ko) * | 2017-08-21 | 2019-08-13 | 서울대학교병원 | 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법 |
| CN109781984A (zh) * | 2019-01-29 | 2019-05-21 | 广州瑞博奥生物科技有限公司 | 一种同时定量检测多个肝癌标志物的抗体芯片试剂盒 |
| CN114560938B (zh) * | 2020-03-30 | 2023-05-23 | 中国人民解放军第四军医大学 | 抗gdf15中和性单克隆抗体及其应用 |
| JP7542920B2 (ja) | 2020-11-26 | 2024-09-02 | 大和製衡株式会社 | 組合せ秤 |
-
2022
- 2022-07-26 EP EP22849488.6A patent/EP4382912A4/en active Pending
- 2022-07-26 WO PCT/JP2022/028776 patent/WO2023008427A1/ja not_active Ceased
- 2022-07-26 US US18/292,652 patent/US20240344134A1/en active Pending
- 2022-07-26 KR KR1020247006286A patent/KR20240046521A/ko active Pending
- 2022-07-26 JP JP2023538551A patent/JPWO2023008427A1/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury | |
| Xie et al. | Characteristics of patients with coronavirus disease (COVID‐19) confirmed using an IgM‐IgG antibody test | |
| JP6941324B2 (ja) | 新規な肝硬変または肝線維症のマーカー | |
| Hiraoka et al. | Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure | |
| Markovic et al. | IL 33 correlates with COVID-19 severity, radiographic and clinical finding | |
| JP4574619B2 (ja) | 肝細胞癌の検査及び監視 | |
| Serfaty | Follow‐up of patients with chronic hepatitis C and a sustained viral response | |
| Xue et al. | Heparin-binding protein levels correlate with aggravation and multiorgan damage in severe COVID-19 | |
| Medeiros et al. | Acute kidney injury associated to COVID-19 leads to a strong unbalance of circulant immune mediators | |
| Chalin et al. | Circulating levels of CXCL11 and CXCL12 are biomarkers of cirrhosis in patients with chronic hepatitis C infection | |
| Elbanan et al. | Assessment of interleukin 17 and transforming growth factor-beta 1 in hepatitis C patients with disease progression. | |
| Aggan et al. | Significance of elevated serum and hepatic NOD-like receptor pyrin domain containing 3 (NLRP3) in hepatitis C virus-related liver disease | |
| JPWO2023008427A5 (https=) | ||
| Hanash et al. | PREVALENCE AND GENOTYPING OF HEPATITIS C VIRUS IN HEMODIALYSIS PATIENTS AND EVALUATION OF HCV-CORE ANTIGEN TEST IN SCREENING PATIENTS FOR DIALYSIS IN SANA'A CITY, YEMEN | |
| US9879320B2 (en) | Combination of biomarkers for the prognosis of response or non-response to an anti-HCV treatment | |
| JP2012515893A5 (https=) | ||
| CN111413502A (zh) | Gp73的新用途及一种基于其的肝组织炎症活动度检测试剂盒 | |
| Liu et al. | Serum ECM1 is a promising biomarker for staging and monitoring fibrosis in patients with chronic hepatitis B | |
| Isaac et al. | Soluble CD163 as a surrogate marker of fibrosis regression in chronic HCV patients receiving direct antiviral agents | |
| Bodakhe et al. | Diagnostic methods for non-alcoholic fatty liver diseases alternative to liver biopsy: a review | |
| Bakır et al. | Assessment of the performances of hepatitis C virus viral markers, age-platelet index and aspartate aminotransferase to alanine aminotransferase ratio scores, in predicting liver histopathology | |
| TW201835573A (zh) | 用以診斷病毒感染的方法 | |
| El Hagary | Study of the Serum Level of Annexin A5 as a Marker for Hepatocellular Carcinoma in Hepatitis C Virus Cirrhosis Patients | |
| Selim et al. | Evaluation of Interleukin-18 as a non invasive marker of liver fibrosis among Chronic hepatitis C virus patients | |
| Quiroga et al. | 752 DETECTION OF ANTIBODIES TO HCV CORE IN PATIENTS WITH SEROLOGICALLY SILENT OCCULT HCV INFECTION |